Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database.
Loading...
Embargo End Date
ICR Authors
Authors
Kantidakis, G
Litière, S
Gelderblom, H
Fiocco, M
Judson, I
van der Graaf, WTA
Italiano, A
Marréaud, S
Sleijfer, S
Mechtersheimer, G
Messiou, C
Kasper, B
Litière, S
Gelderblom, H
Fiocco, M
Judson, I
van der Graaf, WTA
Italiano, A
Marréaud, S
Sleijfer, S
Mechtersheimer, G
Messiou, C
Kasper, B
Document Type
Journal Article
Date
2022-04-01
Date Accepted
2022-03-15
Abstract
BACKGROUND: Soft-tissue sarcomas (STS) constitute a rare group of heterogeneous mesenchymal tumours containing more than 100 histologic subtypes. Here, we investigate whether, and if so, to what extent, skeletal metastases affect the outcome of patients with advanced or metastatic disease. MATERIALS AND METHODS: Selected patients participated in five clinical trials of EORTC-STBSG. Individuals were included if they started treatment with an active drug and had advanced/metastatic STS. The endpoints of interest were overall survival (OS) and progression-free survival (PFS). Univariate and multivariate pooled analyses (after correcting for 12 covariates) were employed with Kaplan-Meier and Cox regression to model the impact of bone metastasis at presentation per treatment line stratified by study. For the subset of patients with bone metastasis, the impact of another metastatic organ site was explored with multivariate Cox regression models. RESULTS: 565 out of 1034 (54.6%) patients received first-line systemic treatment for locally advanced or metastatic disease. Bone metastases were present in 140 patients (77 first-line, 63 second-line or higher). The unadjusted difference in OS/PFS with or without bone metastasis was statistically significant only for first-line patients. For OS, the adjusted hazard ratios for bone metastasis presence were 1.33 (95%-CI: 0.99-1.78) and 1.11 (95%-CI: 0.81-1.52) for first-line/second-line or higher treated patients, respectively. Likewise, the adjusted hazard ratios for PFS were 1.31 (95%-CI: 1.00-1.73) and 1.07 (95%-CI: 0.80-1.43). Effects were not statistically significant, despite a trend in first-line patients for both endpoints. Subgroup analyses indicated bone and lymph node metastasis as the most detrimental combination for OS and bone and lung metastasis for PFS. CONCLUSIONS: Adult STS patients receiving palliative systemic therapy with bone metastasis carried an overall worse prognosis than STS patients without bone metastases. Skeletal metastasis was detrimental for both OS and PFS, independent of the treatment line. Findings may have implications for the management of these patients.
Citation
Sarcoma, 2022, 2022 pp. 5815875 -
Source Title
Sarcoma
Publisher
Wiley
ISSN
1357-714X
eISSN
1369-1643
1369-1643
1369-1643
Collections
Research Team
Sarcoma Clinical Trials